Cisplatin in progressive stage malignancy melanoma.Effect of granisetron hydrochloride on nausea and vomit caused in dacarbazine-vindesine combination therapy.

概要

論文の詳細を見る
Treatment for metastatic melanoma has not yet been established. But the current standard of therapy for metastatic melanoma consists of dacarbazine in combination with other agents. Especially, the combination cisplatin-vindesine-dacarbazine give rise to a high response rate in patients with advanced melanoma. Ten patients with advanced melanoma were treated with a 6-day triple drug chemotherapy regimen comprising cisplatin, dacarbazine and vindesine at the Department of Dermatology, National Cancer Center Hospital. Cisplatin was used in a dose of 80 mg/m2 on day 1, vindesine was used in a dose of 2 mg/m2 on day 2 and dacarbazine was used in a dose of 120 mg/m2 on days 2-6. The major toxicities of cisplatin-vindesine-dacarbazine chemotherapy were nausea and vomiting. Granisetron is a potent and selective 5-HT3 antagonists currently being developed, as an antiemetic for the treatment of chemotherapy induced nausea and vomiting. Granisetron was administered in a dose of 40μg/kg once a day by infusion over 30 minutes, showed an excellent antiemetic effects. Granisetron dramatically reduced or abolished the severe cisplatin-induced vomiting in the absence of any side effects.
日本皮膚悪性腫瘍学会の論文